Regulatory News:
Vitrolife AB (publ) (STO:VITR) :
Third quarter:
· Sales growth was 9 percent in local currency. Sales amounted to SEK 125 (109) million, corresponding to an increase of 15 percent in SEK. Last year’s figure included sales of the transplantation product STEEN Solution™ to Xvivo to the tune of SEK 3 million. Adjusted for this, the increase in sales amounted to 12 percent in local currency.
Help employers find you! Check out all the jobs and post your resume.
